Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2024 / Oct / Skin Sample Success Story
Genetics and epigenetics Technology and innovation Molecular Pathology

Skin Sample Success Story

How an RNA test using small skin samples could provide non-invasive diagnostics for rare diseases

By Jessica Allerton 10/30/2024 News 1 min read

Share

More than 70 percent of rare diseases are of genetic origin, yet only half of such individuals receive a diagnosis following a genetic test. To tackle the imbalance, researchers at the University of Adelaide developed a method that leans on Nobel-prize-winning discoveries to make “silent” genes accessible through more accessible samples. (1).

Credit: Emmylou Nicolas-Martinez

We connected with corresponding author Lachlan Jolly to learn more about this initiative.

How does your new method help find genetic variants?

About one-third of disease-related genes aren’t active in blood or skin samples, making their RNA unavailable without invasive biopsies. We call these “silent” Mendelian genes. We developed two methods based on Nobel Prize-winning discoveries: gene transactivation and cellular transdifferentiation. Both start by growing a small skin sample from the patient in the lab. In gene transactivation, we modify the skin cells to activate the silent gene. In cellular transdifferentiation, we transform the skin cell into another type, like a brain cell, where the silent gene is naturally active. Both methods allow us to study RNA from these silent genes and assess genetic variants.

Specifically, we can see how gene variants affect mRNA processing, leading to two key outcomes. First, it can enable a diagnosis. If a variant disrupts mRNA processing, it suggests that the variant harms gene function and supports its role in causing disease. Second, it opens the door to personalized treatments. Understanding how the variant mRNA is processed can help in designing therapies, such as antisense oligonucleotide treatments like nusinersen (Spinraza), which is approved for spinal muscular atrophy in countries like the US and Australia.

How might your findings change the way we diagnose genetic disorders?

Variants of uncertain significance in silent disease genes make up 22.2 percent of all such variants in ClinVar, a database of human genetic variations and their clinical significance hosted by the National Center for Biotechnology Information. This leaves hundreds of thousands of people worldwide without a genetic diagnosis for their disorder, and this is likely just the tip of the iceberg. Though RNA-based tests can help in around 30 percent of cases, obtaining variant RNA has been difficult because it usually requires invasive biopsies – for example, of the brain. Our new method to obtain variant RNA from silent genes using skin samples offers a less invasive way to conduct RNA-based tests, improving the chances of diagnosis for many patients.

And though more than 90 percent of rare diseases currently have no precision therapies, there are over 14,000 clinical trials underway for such treatments. Access to these trials depends on having a genetic diagnosis. 

Beyond diagnosis, our research highlights the potential to develop new therapies to reverse the harmful effects of gene variants on mRNA. These could include antisense oligonucleotide therapies to change RNA splicing or drugs that modify mRNA decay and translation.

Teaser Image Credit: Olivia Robinson

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. EC Nicolas-Martinez et al., Am J Hum Genet, 111, 8 (2024). PMID: 39084224.

About the Author(s)

Jessica Allerton

Deputy Editor, The Pathologist

More Articles by Jessica Allerton

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Breathing New Life into Diagnostics
Genetics and epigenetics
Breathing New Life into Diagnostics

January 22, 2024

6 min read

Jonathan Edgeworth on how metagenomics could transform testing for respiratory infections

Molecular Spectacular
Genetics and epigenetics
Molecular Spectacular

January 8, 2024

1 min read

A look at last year’s most interesting molecular pathology stories

Redefining Diagnostic Reference Standards
Genetics and epigenetics
Redefining Diagnostic Reference Standards

January 3, 2022

1 min read

Find out what Horizon Discovery’s diagnostic reference standards can do for your workflow

Defining the Next Generation of NGS
Genetics and epigenetics
Defining the Next Generation of NGS

December 31, 2021

1 min read

Overcoming challenges of the typical NGS workflow with the Ion Torrent™ Genexus™ System

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.